Kornimate/medical-research-clean huggingface dataset:
real-world use of novel treatments in patients with spinal muscular atrophy (sma): a multi-site retrospective chart review of pediatric sma patients outside of the united states

Conditions: Spinal Muscular Atrophy

Summary: this global, retrospective, non-interventional, medical chart review (mcr), descriptive study collected patient-level data in regions outside the us. the study required a repeated data collection at follow-up dates from start of treatment with nusinersen, onasemnogene abeparvovec-xioi (oa), and/or risdiplam. at the start of data collection, the study team reached out to the health care providers (hcps) involved in treating pediatric sma patients for participating in this study. the physicians across the participating countries conducted a retrospective mcr of pediatric patients diagnosed with sma who were treated with at least 1of the 3 novel disease-modifying treatments (dmts): nusinersen, oa, and/or risdiplam. all health care encounters data i.e., emergency and inpatient admissions, surgery, and outpatient consultations of recruited patients, including their treatment with nusinersen, oa, and/or risdiplam, were abstracted to understand the treatment patterns as per routine clinical practice for sma management globally. the first date of initial administration of 1 of the 3 target drugs was used as the "index date." based on this, the record abstraction was performed through a retrospective mcr during the pre-index period, at index date and in the post-index period.


Eligibility criteria:
inclusion criteria: * genetically confirmed diagnosis of sma. * aged less than 5 years at index date. * initiated treatment with nusinersen or onasemnogene abeparvovec-xioi or risdiplam or any combination of them during the identification period. * availability of medical information in chart for at least 1 visit prior to initiation of treatment with the target treatment(s). exclusion criteria: none
physical therapy and neuroactive steroids therapy does not modulate serum level of neuroactive steroids

Conditions: Multiple Sclerosis

Summary: this study describes modulation of neuroproprioceptive facilitation and inhibition physical therapy on serum level of neuroactive steroids in multiple sclerosis.

in the parallel group, single blind, randomized controlled trial, participant underwent two kinds of neuroproprioceptive pt (mpat and vrl). at baseline and after the end of the two months' therapeutic program, a blinded assessor evaluated clinical outcomes and data from serum level.

Eligibility criteria:
inclusion criteria: * prevailed spastic paraparesis, stable clinical status and treatment in the preceding 3 months determined by neurologist, * expanded disability status scale score (edss) max. 7.5 exclusion criteria: * other neurological disease or conditions disabling movement

Keywords: neuroactive steroids physical therapy dehydroepiandrosterone cortisol multiple sclerosis
intrauterine lidocaine for laminaria

Conditions: Abortion, Induced; Pain Management

Summary: this is a study to investigate whether instilling a small amount of liquid lidocaine into the uterus will decrease pain felt by women during laminaria insertions done for cervical dilation prior to second trimester abortion. the investigators hypothesize that women who receive intrauterine lidocaine in addition to a paracervical block will experience less pain than women who receive only a paracervical block.


Eligibility criteria:
inclusion criteria: * can sign informed consent * healthy pregnant females * weight over 45kg * seeking abortion by dilation and evacuation in the second trimester of pregnancy * gestational age 14-24 weeks confirmed by clinic ultrasound exclusion criteria: * known allergy or previous reaction to lidocaine, bupivicaine or other anesthetic agent * known allergy or previous reaction to ibuprofen or other nsaid

Keywords: abortion, induced laminaria pain management cervical preparation dilation and evacuation
tegoprazan-containing sequential for h. pylori

Conditions: Helicobacter Pylori Infection

Summary: as h. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional ppi-containing 10-day sequential eradication therapy

eradication treatment containing potassium-competitive acid blocker has shown acceptable eradication efficacy. in regions such as korea, where the prevalence of antimicrobial resistance is high, alternative combinations of antibiotics such as sequential or concomitant therapy are needed. this study compared the outcome of sequential therapy containing tegoprazan, a new potassium-competitive acid blocker, with the conventional esomeprazole-containing sequential therapy.

Eligibility criteria:
inclusion criteria: patients who had h. pylori infection proved by positive test result of urea breath test (ubt), rapid urase test or pathologic examination (warthin-giemsa staining) exclusion criteria: * congestive heart failure, nyha iii or iv * end-stage renal disease * alcoholics * drug abusers * pregnant or nursing women
pda stent in neonates with pda dependent pulmonary circulation

Conditions: Neonatal Cyanosis Due to PDA Dependent Pulmonary Circulation

Summary: after echocardiography confirmation of pda dependent pulmonary circulation in cyanotic neonates, catheter-guided pda stent implantation will be done. under general anasthesia and after discontinuation of prostaglandin 4-6 hours before procedure, obtain vascular access and unfractionated heparin is given, then duct is accessed via a cut pig-tail or judkins right \[jr\] catheter, and is crossed by ptca wire to be carefully placed in the left or right branch pulmonary arteries, choose proper stent diameter and length, place the stent and confirm it's position, nicu admission for the neonate with heparin infusion for 24-48 hrs and acetylsalicylic acid is given then follow up the patient by pulse oximeter and echocardiography


Eligibility criteria:
inclusion criteria: neonates and young infants with duct dependent pulmonary circulation exclusion criteria: * untreated sepsis. * coagulopathy. * pda dependent systemic circulation.
technique and results in endothelial keratoplasty

Conditions: Corneal Endothelial Cell Loss; Fuchs' Endothelial Dystrophy

Summary: to assess and compare the complications and results of different lamellar endothelial keratoplasty techniques and its variations.


Eligibility criteria:
inclusion criteria: 1. diagnosis with corneal endothelial dysfunction requiring lamellar endothelial corneal transplantation. 2. free acceptance to be enrolled in the trial, and signature of the informed consent by the subject and/or its legal representatives. exclusion criteria: n/a

Keywords: corneal endothelial cell loss fuchs' endothelial dystrophy lamellar keratoplasty descemet stripping endothelial keratoplasty descemet membrane endothelial keratoplasty minimal surgical procedure
effect of exercise training in coronary artery disease patients after stenting

Conditions: Stent Restenosis; Coronary Artery Disease

Summary: to determine the effects of exercise training on ankle-brachial index and quality of life in coronary artery disease patients after stenting. there is a need to develop strategies, not only to prevent restenosis but also to improve patients' functional status and perception of well-being. in particular, it is not well defined whether exercise training can reduce the restenosis rate and improve the outcome after percutaneous intervention (pci), and its effects on the ankle-brachial index are not yet well known.

the existence of pad in patients with coronary artery disease (cad) remarkably increases the risk of cardiovascular morbidity and mortality. almost half of the patients, after an initial encouraging improvement in functional capacity and quality of life (qol) after the pci, deal with recurrent chest pain that requires medical attention, reduces functional capacity, and creates a status of psychological distress.

Eligibility criteria:
inclusion criteria: * gcs = 15 * disease chronicity: 1-3 years elective / stenting procedure * single or double vessel stunting ef: 35 above exclusion criteria: * unwilling to participate in research * known cases of uncontrolled dm or htn * known cases of cognitive/memory/neurological disorders * known cases of any systemic disease

Keywords: ankle-brachial index coronary artery diseases exercise training quality of life stenting
clinical evaluation of bioactive resin sealants vs conventional sealants in permanent molars

Conditions: Caries, Dental

Summary: this study will be conducted to evaluate the performance; in terms of retention and caries inhibition; of the newly introduced bioactive resin based pits and fissure sealant versus conventional resin based pits and fissure sealant in caries susceptible fissures in posterior molars in patients at risk of caries. evaluation will be done by visual tactile examination \& vistacam.

in the investigator's study the comparator material will be biocoat® by premier® ; new bioactive resin pits and fissures sealant featuring smartcap™ technology. smartcap™ technology utilizes patented semi-permeable resin microcapsules. in biocoat, the rechargeable smartcap microcapsules are filled with ionic solutions of fluoride, calcium and phosphate, which diffuse in and out of the sealant. greater fluoride uptake in the presence of calcium and phosphate ions is assumed. with limited evidence based information in literature about using bioactive fissure sealants in susceptible fissures , it was found beneficial to evaluate the newly introduced material using a randomized controlled trial to test the null hypothesis that bioactive resin pits and fissure sealant will have the same clinical performance as conventional resin based pits and fissure sealant in susceptible fissures.

Eligibility criteria:
inclusion criteria of participants: * patients with bilateral caries susceptible fissures in molars showing no signs of caries. * 19 - 40 years. * males or females. * co-operative patients approving to participate in the trial. exclusion criteria of participants: * patients younger than 19 years old or older than 40 years old. * pregnancy. * disabilities. * systemic disease or severe medical complications. * allergic history concerning methacrylate. * rampant caries. * heavy smoking. * xerostomia. * lack of compliance. * evidence of severe bruxism, clenching, or tempromandibular joint disorders.
rehabiliation using huber 360 to reduce the risk of falls

Conditions: Rehabilitation; Exercise Therapy; Treatment Outcome; Quality of Life; Fall

Summary: aim: the aim of the present study was to analyse the effects of training performed on a rotating, motorised platform (the huber/spineforce device from lpg systems, valence, france) intended to reduce the risk of falls. subjects: any patient 1) benefiting from a physiotherapy rehabilitation program at the chu liège, cnrf, belgium; 2) presenting a pathological situation justifying functional rehabilitation with huber 360®; 3) presenting any pathology not constituting an exclusion criterion; 4) giving informed consent to research will be include in this 8-week interventional trial. design: randomized open-label trial. patients will be randomized into the intervention group (huber trainig, 45 minutes of training, twice a week during 8 weeks) or in the control group (standard care). outcomes: the effect of the training will be measured on the time-up-and-go test, on the short-physical performance battery test and on quality of life.


Eligibility criteria:
inclusion criteria: * patient benefiting from a physiotherapy rehabilitation program at the chu liège, cnrf * patient presenting a pathological situation justifying functional rehabilitation with huber 360® * patient presenting any pathology not constituting an exclusion criterion * patient giving informed consent to research. exclusion criteria: * cardiac or respiratory or neurological or rheumatological disease incompatible with physical activity ; * joint inflammation; * rheumatic disease in acute phase; * recent trauma, infection of the musculoskeletal system; * fever; * venous thrombosis ; * discopathy in acute phase; * neuropsychological problems that do not allow to integrate the instructions or other serious psychological problems; * cardiovascular diseases and any progressive, chronic, counter-indicative disease; * large anatomical deformities.

Keywords: huber
effect of oral l-carnitine supplement on lipid profile, anemia, and quality of life of patients

Conditions: Complication of Hemodialysis

Summary: the purpose of this study is to determine effect of oral l-carnitine supplement on lipid profile, anemia, and quality of life.

in patients under maintenance hemodialysis several factors reduce the body stored carnitine which in turn affected dyslipidemia, anemia, and general health in these patients. the investigators evaluated the effect of oral l-carnitine supplementation on lipid profiles, anemia, and quality of life in hemodialysis patients.

Eligibility criteria:
inclusion criteria: being in the age range of 18-75 having the history of at least 12 weeks of hemodialysis and at least three times a week and each session almost for four hours having serum triglyceride or total cholesterol concentration \>200 mg/dl or serum hdl concentration \>40 mg/dl in the beginning of the study. exclusion criteria: taking carnitine supplement or the drug that interact with carnation lowering the seizure threshold in the last month being affected by liver function abnormalities, hypothyroidism, chronic infectious diseases (such as hepatitis), inflammatory diseases, cns mass having the history of seizure.

Keywords: renal failure, hemodialysis, dyslipidemia, l-carnitine.
safety, tolerability, and efficacy of aeb071 in the treatment of uveitis

Conditions: Uveitis; Posterior Uveitis; Panuveitis

Summary: the purpose of this study is to assess the safety, tolerability, and efficacy of aeb071 as a therapy for uveitis. vision improvement and reduction in the swelling of retina will be measured for the assessment of efficacy.


Eligibility criteria:
inclusion criteria: * male and female patients with non-infectious intermediate or posterior uveitis or panuveitis in at least one eye, age 18 to 70 years of age inclusive, who are otherwise in good health * macular edema with average central retinal thickness ≥ 250 µm * a vitreous haze score ≥ 1, but ≤ 3 (based on the national eye institute grading system) * best corrected visual acuity no worse than 20/400 and no better than 20/40 * daily prednisone dose \< 1 mg/kg exclusion criteria: * patients with choroidal neovascularization. * patients with the following forms of uveitis: 1. serpiginous choroidopathy 2. acute multifocal placoid pigment epitheliopathy 3. white dot retino-choroidopathies (e.g., multiple evanescent white dot syndrome (mewds) or multifocal choroiditis) * macular edema associated with other ocular disease (e.g., diabetic retinopathy) * patients who had a prior vitrectomy * any eye condition that may affect the evaluation of visual acuity and retinal thickness * concurrent use of certain immunosuppressive agents (specific washout periods for different agents are defined in the protocol) * use of systemic medications known to be toxic to the lens, retina, or optic nerve (e.g. deferoxamine, chloroquine, and ethambutol) currently or in the past 6 months * other protocol-defined inclusion/exclusion criteria may apply

Keywords: uveitis macular edema
colorectal cancer screening validation study

Conditions: Colorectal Cancer Screening

Summary: the purpose of this study is to evaluate the gene expression patterns from colorectal mucosal cells collected through the use of a standard anoscope and cytology brush. patients will include those scheduled for routine colonoscopy procedures and those with confirmed colorectal cancer.


Eligibility criteria:
inclusion criteria: * willing to provide informed consent * greater than or equal to 50 years of age * patient is scheduled for routine colonoscopy procedure or colorectal cancer surgery * subject is willing to provide colorectal mucosal sample for gene expression testing exclusion criteria: * recent radiation or treatment for gynecologic, prostate or rectal cancer * recent surgery for anal rectal disease * polys, family or self history of cancer (control group only) * gi disease * any mucosal disease or systemic condition that may confound the scientific interpretation of the gene expression results

Keywords: colorectal cancer screening gene expression rtpcr
the prediction model of hypoxemia for safe bronchoscopy

Conditions: Hypoxemia; Obstructive Sleep Apnea

Summary: the purpose of this study is to develop the hypoxemia prediction model during fiberoptic bronchoscopy under mac(monitored anesthesia care) anesthesia.

currently, diverse sedatives and analgesic methods are used during fiberoptic bronchoscopy for reducing patients' discomfort and facilities of procedures as british thoracic society recommendation. mac anesthesia, one of the widely used sedative method during bronchoscopy, have many advantages, occurrence of respiratory depression, hypoxemia are not uncommon during the procedures. the investigators try to find out risk factors and develop the prediction model for hypoxemia during bronchoscopy under mac anesthesia.

Eligibility criteria:
inclusion criteria: * age\> 15 yrs * patients who are planned to get fiberoptic bronchoscopy under mac anesthesia in seoul national university bundang hospital exclusion criteria: * patients who will get endobronchial ultrasound guided transbronchial needle aspiration * patients whose baseline oxygen saturation is below 90% * intubated patients * patients do not agree with the study enrollment

Keywords: hypoxemia model bronchoscopes monitored anesthesia care
myocardial blood flow by 15o water pet

Conditions: Coronary Heart Disease

Summary: coronary heart disease is a very common condition caused by narrowings in the blood vessel supplying the heart. the investigators are studying new tests to diagnose heart disease. in this study the investigators plan to investigate a special scan called a pet/ct (positron emission tomography/computed tomography) and a new type of ct (computed tomography) scan to tell us about the flow of blood to the heart muscle.

participants will undergo pet/ct with oxygen-15 labelled water and computed tomography myocardial perfusion imaging.

Eligibility criteria:
inclusion criteria: * suspected coronary artery disease exclusion criteria: * inability or unwillingness to undergo ct or pet imaging * renal failure (serum creatinine \>200 um/l or egfr \<30 ml/min) * hepatic failure * allergy to iodinated contrast * pregnancy * contraindication to adenosine * inability to give informed consent * atrial fibrillation with a fast ventricular rate (\>70 beats per minute)

Keywords: coronary heart disease computed tomography myocardial perfusion positron emission tomography oxygen 15 labelled water myocardial perfusion myocardial blood flow
study of eyes and attention deficit (sead)

Conditions: ADHD; Convergence Insufficiency; Accommodative Insufficiency

Summary: attention-deficit hyperactivity disorder (adhd) is considered to be one of the most prevalent chronic health conditions in children. it affects between 4% and 12% of young children. a relationship between convergence insufficiency (eye teaming) and adhd has been shown. however, the effect of adhd medications on focusing and eye teaming has not been previously investigated. therefore, the purpose of this study is to determine the effect of adhd medication on focusing and eye teaming skills.


Eligibility criteria:
inclusion criteria: * best corrected visual acuity of 20/25 in both eyes at distance and near; * willingness to wear eyeglasses or contact lenses to correct refractive error, if necessary; * 500" random dot stereopsis exclusion criteria: * amblyopia (lazy eye); * eye disease
anxiety and vagal control of the heart in coronary disease

Conditions: Cardiovascular Diseases; Coronary Disease; Depression; Heart Diseases; Death, Sudden, Cardiac; Arrhythmia

Summary: to examine the role of reduced vagal control of heart rate in the increased risk of cardiac mortality associated with anxiety in a population with established coronary artery disease (cad). a second objective is to determine whether the effects of anxiety are independent of the effects of depression.

background: coronary heart disease continues to be the leading cause of death in the united states, despite risk factor reduction and technological advances in treatment options. prospective studies implicate chronic anxiety as an independent risk factor for fatal coronary heart disease. in particular, anxiety increases the risk of sudden cardiac death substantially. design narrative: nine hundred and fifty cad patients were recruited for this study from patients hospitalized for elective cardiac catheterization. anxiety was measured by the hospital anxiety scale, the spielberger trait anxiety inventory, and the crown-crisp phobic anxiety scale. symptoms of depression were measured by the montgomery-asberg depression rating scale, the hospital depression scale, and the beck depression inventory. vagal control of heart rate was determined using power spectral analysis to measure two indices of vagal control: baroreceptor-mediated vagal reflex cardiac control, and respiratory sinus arrhythmia. patients were followed at 6 months, l year, 2 years, and 3 years postcatheterization, and cardiac mortality data were obtained, including non-sudden and sudden cardiac death. the data generated by this study were used to examine the involvement of impaired vagal cardiac control in the risk of fatal coronary heart disease and sudden cardiac death associated with anxiety. specifically, the study examined: (1) the relationship between anxiety and cardiac mortality; (2) the relationship between anxiety and vagal control; (3) the role played by reduced vagal control in mediating anxiety-related risk; and (4) the relationship between depression, vagal control and cardiac risk. findings of a relationship between anxiety, reduced vagal control and sudden cardiac death would suggest the potential importance of early intervention in cardiac patients with anxiety disorders and would underscore the benefit of aggressive monitoring of arrhythmias in this population, which may ultimately translate to reduced mortality rates. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
improving the diagnosis of traveller's fevers in point of care (poc)

Conditions: Traveller's Fever

Summary: a point-of-care laboratory (poc) was set at north hospital, marseille, france for the diagnosis in less than two hours of traveller's fever caused by known pathogens, close to the reception of emergency service. in this instance 30% of patients have no etiological diagnosis after the poc traveller's fever tests . the objective of this study is to implement a new diagnosis strategy relying on the hypothesis that a rectal swab would improve the etiological diagnosis of traveller's fever of at least 10%.


Eligibility criteria:
inclusion criteria: * patient admitted for traveller's fever requiring a microbiological examination with a "traveller's fever poc kit" * patient who freely signed the informed consent form * patient affiliated to a social security regime exclusion criteria * pregnant or breastfeeding women * adult patient under guardianship * patient deprived with liberty under court order * patient refusing or unable to sign the informed consent form